Hans Pharma (03692.HK): B7-H4 targeted antibody-drug conjugate HS-20089 included as a breakthrough therapy by China's National Medical Products Administration.

Intelligence Finance and Economics APP News, Hanson Pharmaceuticals (03692.HK) announced that on May 1, 2025, the group's self-developed B7-H4 targeted antibody-drug conjugate (ADC) injection HS-20089 ("the product") has been approved by the National Medical Products Administration of China (NMPA) as a breakthrough therapy drug, with the intended indication for use in patients with platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.